patient is suffering from aggressive haematological disease AND has undergone at least two lines of previous therapies AND/OR has undergone at least one previous therapy and no standard treatment is available in the specific disease setting and disease specific guidelines recommend treatment in studies.
duration of last response is less than 6 months defined as first day of last treatment to date of relapse, the response duration has to be available with dates (dd/mm/yyyy) for initiation of and relapse to previous treatment.
best response to previous treatment has to be available.
The patient is able to give written informed consent and wishes to undergo further therapy
further therapy is medically feasible
tumor cell-containing samples can be obtained
You may not be if
current participation in another experimental clinical trial
performance status does not allow participation (ECOG ˃ 1)
pregnancy, tested at screening
patient suffers from classical or nodular, lymphocyte predominant Hodgkins lymphoma.
other malignoma, diagnosed \<1a before inclusion (except localized squamous cell carcinoma of the skin, surgically curable melanoma of the skin, basal cell carcinoma of the skin)
Clareo Health | Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies
